Form 4: Akero Therapeutics Director Judy Chou Acquires 26,000 Stock Options
SEC Form 4 Filing
Director Judy Chou acquired 26,000 stock options in Akero Therapeutics, Inc. on June 8, 2024.
Summary
- On June 8, 2024, Judy Chou, a director of Akero Therapeutics, Inc., acquired 26,000 stock options.
- The exercise price of these options is $23.02.
- The options vest fully on the earlier of June 7, 2025, or the next annual meeting of the Company's stockholders, contingent upon continued service on the Board.
- The options expire on June 7, 2034.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, which is neutral in sentiment.
Industry Context
This is a standard Form 4 filing, reflecting a director's acquisition of stock options, which is a common form of executive compensation in the biotechnology industry.
Stakeholder Impact
- The acquisition of stock options by a director can be seen as a positive sign, aligning the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/08/2024 | Date of transaction: Judy Chou acquired 26,000 stock options. |
| 06/07/2025 | Earliest vesting date for the stock options, contingent on continued service on the Board. |
| 06/07/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.